Genmab Announces Topline Results in Phase III study of Arzerra® in Indolent Non-Hodgkin’s Lymphoma
Topline results from Phase III study in iNHL did not meet primary endpoint of improved progression-free survival Genmab A/S (Nasdaq…
Topline results from Phase III study in iNHL did not meet primary endpoint of improved progression-free survival Genmab A/S (Nasdaq…
Potentially first new class of antibiotics in Phase III development against Gramnegative pathogens in 50 years Polyphor today announced the…